蔚蓝生物
(603739)
| 流通市值：38.36亿 | | | 总市值：38.36亿 |
| 流通股本：2.53亿 | | | 总股本：2.53亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 945,618,593.2 | 609,232,865.6 | 286,784,227.66 | 1,198,902,103.15 |
| 营业收入 | 945,618,593.2 | 609,232,865.6 | 286,784,227.66 | 1,198,902,103.15 |
| 二、营业总成本 | 881,905,556.31 | 570,646,821.37 | 273,764,144.88 | 1,093,894,635.23 |
| 营业成本 | 527,857,116 | 336,463,438.96 | 159,293,541.73 | 644,687,499.1 |
| 税金及附加 | 9,913,292.49 | 6,872,734.74 | 3,355,090.96 | 9,881,766.88 |
| 销售费用 | 139,421,562.36 | 93,489,672.26 | 43,757,679.08 | 189,684,616.46 |
| 管理费用 | 107,265,270.05 | 68,724,411.94 | 35,634,701.78 | 124,776,474.34 |
| 研发费用 | 81,303,889.41 | 55,052,493.39 | 26,717,261.31 | 110,681,959.47 |
| 财务费用 | 16,144,425.99 | 10,044,070.08 | 5,005,870.02 | 14,182,318.98 |
| 其中:利息费用 | 16,374,941.9 | 10,677,030.94 | 5,410,325.34 | 15,218,209.81 |
| 其中:利息收入 | -1,193,650.95 | -799,165.44 | -493,758.29 | 1,584,187.85 |
| 加:公允价值变动收益 | 470,143.27 | 7,949,648.34 | 38,146 | 9,220,190.93 |
| 加:投资收益 | 3,965,899.11 | -3,039,213.92 | 4,575,081.09 | 6,416,063.94 |
| 资产处置收益 | 566,953.65 | 559,819.91 | 520,673.21 | 550.46 |
| 资产减值损失(新) | 519,852.13 | 519,852.13 | - | -6,519,140.77 |
| 信用减值损失(新) | -3,865,898.14 | -1,435,182.77 | -1,839,691.1 | -13,341,312.05 |
| 其他收益 | 17,042,774.3 | 12,105,539.28 | 6,323,700.16 | 22,116,785.28 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 82,412,761.21 | 55,246,507.2 | 22,637,992.14 | 122,900,605.71 |
| 加:营业外收入 | 72,607.52 | 47,910.55 | 21,206.79 | 80,268.24 |
| 减:营业外支出 | 51,783.28 | 13,080.49 | 4,284.55 | 485,719.58 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 82,433,585.45 | 55,281,337.26 | 22,654,914.38 | 122,495,154.37 |
| 减:所得税费用 | 21,365,718.55 | 12,970,815.11 | 5,492,396.3 | 19,637,913.94 |
| 六、净利润 | 61,067,866.9 | 42,310,522.15 | 17,162,518.08 | 102,857,240.43 |
| 持续经营净利润 | 61,067,866.9 | 42,310,522.15 | 17,162,518.08 | 102,857,240.43 |
| 归属于母公司股东的净利润 | 40,847,212.04 | 29,351,998.09 | 12,722,943.82 | 80,706,911.48 |
| 少数股东损益 | 20,220,654.86 | 12,958,524.06 | 4,439,574.26 | 22,150,328.95 |
| (一)基本每股收益 | 0.16 | 0.12 | 0.05 | 0.32 |
| (二)稀释每股收益 | 0.16 | 0.12 | 0.05 | 0.32 |
| 八、其他综合收益 | -58,423.12 | -57,264.08 | -4,237.35 | 573,111.07 |
| 归属于母公司股东的其他综合收益 | -41,480.72 | -39,654.34 | -2,845.8 | 583,781.21 |
| 九、综合收益总额 | 61,009,443.78 | 42,253,258.07 | 17,158,280.73 | 103,430,351.5 |
| 归属于母公司股东的综合收益总额 | 40,805,731.32 | 29,312,343.75 | 12,720,098.02 | 81,290,692.69 |
| 归属于少数股东的综合收益总额 | 20,203,712.46 | 12,940,914.32 | 4,438,182.71 | 22,139,658.81 |
| 公告日期 | 2024-10-29 | 2024-08-28 | 2024-04-26 | 2024-04-26 |
| 审计意见(境内) | | | | 标准无保留意见 |